This company listing is no longer active
Odonate Therapeutics Management
Management criteria checks 3/4
Key information
Kevin Tang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.8yrs |
| CEO ownership | n/a |
| Management average tenure | 6.1yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$119m |
| Mar 31 2021 | n/a | n/a | -US$130m |
| Dec 31 2020 | US$1 | US$1 | -US$126m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$118m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$1 | US$1 | -US$112m |
| Sep 30 2019 | n/a | n/a | -US$113m |
| Jun 30 2019 | n/a | n/a | -US$110m |
| Mar 31 2019 | n/a | n/a | -US$101m |
| Dec 31 2018 | US$1 | US$1 | -US$89m |
| Sep 30 2018 | n/a | n/a | -US$76m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$1 | US$1 | -US$33m |
| Sep 30 2017 | n/a | n/a | -US$19m |
| Jun 30 2017 | n/a | n/a | -US$10m |
| Mar 31 2017 | n/a | n/a | -US$6m |
| Dec 31 2016 | US$1 | US$1 | -US$3m |
Compensation vs Market: Insufficient data to establish whether Kevin's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Tang (55 yo)
9.8yrs
Tenure
US$1
Compensation
Mr. Kevin C. Tang serves as Director at Tetraphase Pharmaceuticals, Inc. since July 28, 2020. He has been the Chairman and Chief Executive Officer at Odonate Therapeutics, Inc. since 2013. He served as the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | US$1.00 | no data | |
| CFO & Principal Accounting Officer | 4yrs | US$572.17k | 0.0089% $ 3.9k | |
| Senior Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Technical Operations | 6.3yrs | no data | no data | |
| Chief Scientific Officer | 4yrs | no data | no data | |
| Chief Development Officer | 6.1yrs | no data | no data | |
| Senior Vice President of Quality Assurance | no data | no data | no data | |
| Senior Vice President of Program Management & Technology | no data | no data | no data | |
| Senior Vice President of Clinical Operations | no data | no data | no data |
6.1yrs
Average Tenure
55yo
Average Age
Experienced Management: 4OD's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | US$1.00 | no data | |
| Independent Director | 3.9yrs | US$249.44k | 0% $ 0 | |
| Independent Director | 5.9yrs | no data | 1.51% $ 663.4k | |
| Independent Director | 5.3yrs | US$274.44k | 0.010% $ 4.5k | |
| Director | 5.3yrs | US$249.44k | 0% $ 0 |
5.3yrs
Average Tenure
57yo
Average Age
Experienced Board: 4OD's board of directors are considered experienced (5.3 years average tenure).